Skip to main navigation ABOUT US PATIENTS & FAMILIES PRODUCTS PIPELINE CAREERS INVESTORS Contact Us Press Releases Statement on Our Commitment to Diversity and Equality Statement on COVID-19 As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders. Keyword Search Year 2021 Date Title 11/22/21 Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders 11/9/21 Neurocrine Biosciences to Present at Upcoming Healthcare Conferences 11/1/21 Neurocrine Biosciences Reports Third Quarter 2021 Financial Results 11/1/21 Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021 10/16/21 Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting 10/11/21 Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results 10/8/21 Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic 9/10/21 Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021 9/2/21 Neurocrine Biosciences to Present at Upcoming Healthcare Conferences 8/5/21 Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease 8/3/21 Neurocrine Biosciences Reports Second Quarter 2021 Financial Results 7/22/21 Neurocrine Biosciences/The Harris Poll Survey: 8 in 10 Americans Will Always Prefer In-Person Doctor Appointments to Telehealth 7/19/21 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results 7/8/21 Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 6/1/21 Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference 5/11/21 Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference 5/5/21 Neurocrine Biosciences Reports First Quarter 2021 Financial Results 5/4/21 Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference 5/3/21 Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week 4/16/21 Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors 4/14/21 Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results 4/8/21 Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting 3/25/21 Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day 3/20/21 Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021 3/9/21 Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference 3/2/21 Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) 2/23/21 Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference 2/4/21 Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results 1/20/21 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results 1/8/21 Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones 1/4/21 Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference INVESTORS INVESTORS Press Releases Stock Quote SEC Filings Shareholder Contacts Partners/Collaborators Annual Meeting Online Annual Reports Ownership Email Alerts Corporate Governance Corporate Sustainability Webcasts & Presentations INVESTOR TOOLKIT INVESTOR TOOLKIT Print Page RSS Feeds E-mail Alerts IR Contacts ©2021 Neurocrine Biosciences, Inc. All Rights Reserved. Privacy Policy Terms & Conditions Sitemap CP-NBI-US-0001 08/16